Vera Therapeutics, Inc. (VERA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$31.97+4.10%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VERA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -60.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
VERA — officer change
Dated 2026-07-09
Chief Regulatory Officer — William Turner: William Turner transitions to Special Advisor for Regulatory Affairs with Nancy Bowman, M.D., Ph.D. succeeding as Chief Regulatory Officer.
Why it matters: The data can test whether TRUTAKNA slows kidney function loss over time. The final analysis showed a 5.0 mL/year treatment effect.
Supportive ifThe Q1 2027 two-year eGFR data show a treatment effect near the reported 5.0 mL/min/1.73m² per year, with p<0.0001.
Worry ifThe full two-year data fail to confirm the reported eGFR benefit or show a treatment effect near zero.
Why it matters: Cash use rose as Vera built its launch and ran trials. Faster spending could shorten its funding runway.
Worry ifIn its next report, Vera's six-month operating cash use is no higher than $206.8 million.
Less concerning ifIn its next report, six-month operating cash use is above $206.8 million.
Why it matters: The filing is the next step toward full FDA approval. A delay could push that path back.
Supportive ifVera submits the supplemental BLA to the FDA by December 31, 2026.
Worry ifVera reports that the supplemental BLA will be filed after Q4 2026.
Why it matters: Full approval would confirm the path from accelerated approval. A delay or rejection would weaken it.
Supportive ifThe FDA grants full approval for TRUTAKNA in IgAN in 2027.
Worry ifThe FDA does not grant full approval in 2027, or asks for more trial data.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $476 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,197 loss on $10,000 · 52.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More patient starts would show that early launch interest is turning into use. Fewer starts could point to slower uptake.
Supportive ifA later company update reports more than 350 additional patient start forms after the first ten weeks.
Worry ifA later update reports fewer than 350 new patient start forms over a similar period, or says starts have stopped.